Haleon invests $54.2 million in Richmond facility to expand research capabilities

Richmond, Virginia – Haleon, a global consumer health company, is making a significant investment in Richmond with a $54.2 million upgrade to its research and development facility. Governor Glenn Youngkin announced the expansion, highlighting its impact on Virginia’s growing pharmaceutical sector and reinforcing the state’s reputation as a leader in healthcare innovation.

Governor Youngkin met with Haleon executives in London in 2024 to discuss the project, which will modernize the Richmond facility by incorporating new technologies and expanding research capabilities. The investment solidifies Virginia’s status as a business-friendly state, attracting major companies that drive economic growth and scientific advancements.

Boosting Research and Workforce Development in Virginia

Beyond the facility upgrades, Haleon is collaborating with Virginia Commonwealth University (VCU) and the state to launch the Haleon-Commonwealth Consumer Healthcare Internship Program for Advanced Life Sciences. This initiative, supported equally by the company and the Commonwealth, is designed to provide hands-on learning opportunities for students pursuing careers in pharmaceutical sciences.

Through this five-year paid internship program, undergraduate students enrolled in VCU’s Pharmaceutical Science degree program will receive direct exposure to cutting-edge research. The program also extends summer internship opportunities to students from all Virginia higher education institutions, fostering a skilled workforce in consumer healthcare.

“Our investment in the modernization of the lab space at our Research & Development facility is an investment in delivering on our mission of everyday health with humanity as well as the Richmond community,” said Haleon North America President Lisa Paley. “We are further excited by our partnership with the Commonwealth to co-fund a five-year paid internship program to build Richmond as a Life Science Hub and develop the future workforce.”

A Longstanding Commitment to Richmond and Innovation

Haleon’s Richmond presence dates back to the 1960s, evolving over time through mergers, acquisitions, and scientific advancements. The facility has played a critical role in developing and growing world-renowned brands, including Advil, Emergen-C, and Robitussin.

Over the past few years, the Richmond site has expanded its workforce, adding 100 new employees since 2020. The facility is home to a Center of Excellence in Research & Development, featuring key functions such as consumer science, formulation development, microbiology, and packaging design.

“Haleon’s decision to upgrade their space here in Richmond is a vote of confidence in Virginia’s life sciences ecosystem and in where they want to invest and grow globally,” said Secretary of Commerce and Trade Caren Merrick.

The expansion is also expected to strengthen Richmond’s position as a national hub for pharmaceutical research and innovation. City of Richmond Mayor Dr. Danny Avula emphasized the impact of the investment on the local economy and workforce.

“This is a significant investment from Haleon,” Avula said. “It helps boost the Richmond economy and serves as a testament to the City’s role as a hub for innovation and talent. We are proud to be home to Haleon and grateful for the company’s commitment to providing high-quality jobs and advancing health care research in this community.”

Support from State and Economic Development Partners

The Virginia Economic Development Partnership collaborated with the City of Richmond and the Greater Richmond Partnership to secure the expansion. Governor Youngkin approved a $950,000 Virginia Investment Performance Grant, an incentive designed to encourage existing Virginia companies to continue capital investment in the state.

The project is receiving widespread support from both state and local leaders, including Senator Lamont Bagby and Delegate Rae Cousins, who emphasized the importance of fostering research, job creation, and student learning opportunities in the life sciences sector.

“Haleon is leading groundbreaking work in the pharmaceutical field, and I am excited they have committed to continuing to invest right here in Richmond,” said Senator Bagby.

Haleon’s transformation into an independent consumer health company in 2022 further underscores its long-term vision for growth. The Richmond facility remains a key research and development site, driving advancements in pharmaceutical sciences and consumer healthcare.